Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism

  • Maurer G. 
  • Schreier E. 
  • Delaborde S. 
  • Nufer R. 
  • Shukla A. P. 


The disposition and biotransformation of bromocriptine were investigated in mouse, rat, dog, rhesus monkey and man following administration of the drug substance labelled with either tritium or carbon-14.

The enteral absorption of bromocriptine was incomplete and amounted to 30–40% of the dose as estimated directly from the sum of biliary and urinary excretion of radioactive compounds in bile duct cannulated rats and monkeys. The main route of elimination was the bile (80–93% of the absorbed dose). Only 1 to 6% of the radioactive dose was recovered in urine of intact animals and man.

Extensive biotransformation of bromocriptine is reflected by very complex metabolite profiles in all tested body fluids and by the almost complete absence of parent drug in urine and bile. Of the numerous drug-derived radioactive components seventeen could be identified. In animals the major urinary metabolites were 2-bromo-lysergic acid (7), its amide (3), and the respective isomers at position 8, metabolites6 and1. Bromolysergic acid (7) and bromoisolysergic acid (6) accounted for half of the radioactivity in human urine. In rat and monkey bile up to 40% of the radioactivity was associated with metabolites derived from the oxidation (hydroxylation, ring-opening) of the proline fragment (4, 5, 21–24, 29–31). The hydroxylated compounds were present in the form of conjugates with glucuronic acid. These were subsequently deconjugated in the intestine and recovered in the faeces as the free forms.

The presence of the parent drug as a major component in rat plasma following intravenous administration and its absence after oral administration indicated that the elimination of bromocriptine proceeded almost entirely by metabolism in the liver.In vitro studies with isolated rat hepatocytes and 10.000 g supernatant of human liver confirmed thein vivo findings.

Based on the structures of the identified metabolites it could be concluded that the biotransformation of bromocriptine in man occurred through the same principal pathways as in all investigated animal species.

Key words

Ergopeptine metabolism animals man in vitro 


  1. 1.
    Maurer, G., Schreier, E., Delaborde, S., Loosli, H.R., Nufer, R. and Shukla, A.P. (1982): Fate and disposition of bromocriptine in animals and man. I: Structure elucidation of the metabolites. Eur. J. Drug. Metab. Pharmacok.7, 281–292.Google Scholar
  2. 2.
    Schreier, E. (1976): Radiolabelled peptide ergot alkaloids. Helv. chim. Acta59, 585–606.CrossRefPubMedGoogle Scholar
  3. 3.
    Meszaros, J., Nimmerfall, F., Rosenthaler, J., Weber, H. (1975): Permanent bile duct cannulation in the monkey. A model for studying intestinal absorption. Europ. J. Pharmacol.32, 233–242.CrossRefGoogle Scholar
  4. 4.
    Bahr, C., Groth, C.G., Jansson, H., Lundgren, G., Lind, M., Glauman, H. (1980): Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin. Pharmacol. Ther.27, 711–725.Google Scholar
  5. 5.
    Bradford, M. (1976): A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem.72, 248–254.CrossRefPubMedGoogle Scholar
  6. 6.
    Eckert, H., Kiechel, J.R., Rosenthaler, J., Schmidt, R., Schreier, E. (1978): Biopharmaceutical aspects. Analytical methods, pharmacokinetics, metabolism and bioavailability. In: Berde, B., Schild, H.O. (eds): Ergot alkaloids and related compounds. Handbook Exp. Pharmacol.49, 719–803, Berlin, Heidelberg, New York: Springer.Google Scholar
  7. 7.
    Aellig, W.H., Nüesch, E. (1977): Comparative pharmacokinetic investigations with tritium labelled ergot alkaloids after oral and after intravenous administration in man. Int. J. clin. Pharmacol.15, 106–112.Google Scholar
  8. 8.
    Schran, H.F., Bhuta, S.I., Schwarz, H.J., Thorner, M.O. (1980): The pharmacokinetics of bromocriptine in man. In: Goldstein, M., Calne, D.B., Lieberman, A., Thorner, M.O. (eds): Ergot compounds and brain function: Neuroendocrine and neuropsychiatric aspects, pp. 125–139. New York: Raven Press.Google Scholar
  9. 9.
    Meier, J., Tanner, P., Sandoz Ltd. Basle, unpublished data.Google Scholar
  10. 10.
    Markey, S.P., Colburn, R.W., Kopin, I.J. Aamodt, R.L. (1979): Distribution and excretion in the rat and monkey of [82Br]bromocriptine. J. Pharmacol. Exp. Ther.211, 31–35.PubMedGoogle Scholar
  11. 11.
    Wong, S.H., Spencer, R.P., Hosain, P. (1978): Distribution and fate of 2-Br-82-alpha-ergokryptine and H-3-dihydroergokryptine in female rabbits. Fed. Proc.37, 741, Abstract No. 2773.Google Scholar
  12. 12.
    Giron-Forest, D.A., Schönleber, W.D. (1979): Bromocriptine methanesulphonate. An analytical profile. In: Florey, K. (ed.): Analytical profiles of drug substances. Vol.8, pp. 47–81. New York, London: Academic Press.Google Scholar
  13. 13.
    Larsen, N.E., Oehman, R., Larsson, M., Hvidberg, E.F. (1979): Determination of bromocriptine in plasma: Comparison of gas chromatography, mass fragmentography and liquid chromatography. J. Chromatography174, 341–349.CrossRefGoogle Scholar
  14. 14.
    Price, P., Debono, A., Parkes, J.D., Mardsen, C.D., Rosenthaler, J. (1978): Plasma bromocriptine levels, clinical and growth hormone responses in parkinsonism. Brit. J. Clin. Pharmacol.6, 303–309.Google Scholar
  15. 15.
    Schran, H.F., Schwarz, H.J., Talbot, K.C., Loeffler, L.J. (1979): Specific analysis of ergot peptide alkaloids by radioimmunoassay. Clin. Chem.25, 1928–1933.PubMedGoogle Scholar
  16. 16.
    Fletcher, S., Vardi, J., Oberman, Z., Gilad, S., Allelov, M., Streifler, M. (1979): Plasma levels of bromocriptine after acute and chronic administration in parkinsonian patients: a radioimmunoassay study. Curr. Ther. Res.25, 540–543.Google Scholar
  17. 17.
    Pearce, I., Pearce, J.M.S. (1978): Bromocriptine in parkinsonism. Brit. med. J.1, 1402–1404.CrossRefPubMedGoogle Scholar
  18. 18.
    Thorner, M.O., Schran, H.F., Evans, W.S., Rogol, A.D., Morris, J.L., MacLeod, R.M. (1980): A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women. A study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J. Clin. Endocrinol. Metab.50, 1026–1033.CrossRefPubMedGoogle Scholar
  19. 19.
    Nimmerfall, F., Rosenthaler, J. (1976): Ergot alkaloids: hepatic distribution and estimation of absorption by measurement of total radioactivity in bile and urine. J. Pharmacokinet. Biopharm.4, 57–66.CrossRefPubMedGoogle Scholar
  20. 20.
    Friis, M.L., Gron, U., Larsen, N.E., Pakkenberg, H., Hvidberg, E.F. (1979): Pharmacokinetics of bromocriptine during continuous oral treatment of parkinson’s disease. Europ. J. Clin. Pharmacol.15, 275–280.CrossRefGoogle Scholar
  21. 21.
    Friis, M.L., Paulson, O.B., Hertz, M.M. (1979): Transfer of bromocriptine across the blood-brain barrier in man. Acta Neurol. Scand.59, 88–95.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • Maurer G. 
    • 2
  • Schreier E. 
    • 2
  • Delaborde S. 
    • 2
  • Nufer R. 
    • 2
  • Shukla A. P. 
    • 2
  1. 1.Chemistry DepartmentUniversity of JaipurJaipurIndia
  2. 2.Pharmaceutical Research and DevelopmentSandoz LtdBasleSwitzerland

Personalised recommendations